Skip to main content
SpringerLink
Log in
Book cover

Handbook of Evidence-Based Radiation Oncology pp 563–582Cite as

Hodgkin’s Lymphoma

  • Chapter
  • First Online:

  • 2737 Accesses

Abstract

Epidemiology Incidence/mortality in the US for 2008 is 8,220/1,350. Males slightly greater than females (1.1:1). Bimodal peak: ages 25–30 and >55. First-degree relatives of patients have fivefold increase in risk for Hodgkin’s disease. Associated with Epstein–Barr virus, which is associated with mixed cellularity subtype. EBV DNA has been detected in Reed-Sternberg cells. Associated with HIV infection.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

References

  • Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s Disease. J Clin Oncol 2007;25(25):3902–3907.

    Article  PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tomasic R, et al. Involved field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2007;67(1):19–30.

    Article  PubMed  Google Scholar 

  • Aleman BMP, Raemaekers JMM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 2003;348:2396–2406.

    Article  PubMed  Google Scholar 

  • Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992;327:1478–1484.

    Article  CAS  Google Scholar 

  • Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002;346:1417–1418.

    Article  PubMed  Google Scholar 

  • Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258–2272.

    PubMed  CAS  Google Scholar 

  • Diehl V, Brillant C, Engert A, et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol (Meeting abstracts) 2005a; 23:6506.

    Google Scholar 

  • Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin’s lymphoma. Blood 2005b;106:(abstract no. 816)

    Google Scholar 

  • Diehl V, Franklin J, Pfistner B, et al. Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). J Clin Oncol (Meeting abstracts) 2007;25:LBA8015.

    Google Scholar 

  • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. NEJM 2003;348:2386–2395.

    Article  PubMed  CAS  Google Scholar 

  • Diehl V, Franklin J, Tesch H, et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin’s disease in the HD9 trial of the German Hodgkin’s Lymphoma Study Group (GHSG). Proc ASCO 2007 (abstract no. 7).

    Google Scholar 

  • Diehl V, Haverkamp H, Mueller R, et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP baseline with or without readiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the Germa Hodgkin Study Group (GHSG). J Clin Oncol 2009;27:15s (Suppl; abstr 8544).

    Article  Google Scholar 

  • Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol. 1995;6(9):901–910.

    PubMed  CAS  Google Scholar 

  • Eich H, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma – analysis of a quality control program initiated by the Radiotherapy Reference Center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2007;69:1187–1192.

    Article  PubMed  Google Scholar 

  • Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27(27):4548–4554.

    Article  PubMed  Google Scholar 

  • Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003;21:3601–3608.

    Article  PubMed  Google Scholar 

  • Engert, A, Franklin, J, Eich H, et al. Two cycles of doxorubicin, bleomycin, vinblastine and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 Trial. J Clin Oncol 2007;25(23): 3495–3502.

    Article  PubMed  CAS  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994;120(11):903–912.

    Article  PubMed  CAS  Google Scholar 

  • Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007;357(19):1916–1927.

    Article  PubMed  CAS  Google Scholar 

  • Ferme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’etudes des Lymphomes de l’Adulte H89 trial. Blood 2000;95:2246–2252.

    PubMed  CAS  Google Scholar 

  • Gallmini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.

    Article  Google Scholar 

  • Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008;88:202–210.

    Article  PubMed  Google Scholar 

  • Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced stage Hodgkin’s lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198–9207.

    Article  PubMed  CAS  Google Scholar 

  • Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998;339:1506–1514.

    Article  PubMed  CAS  Google Scholar 

  • Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin’s disease: mature data in early and advanced stage patients. Blood 2004;104(abstr 308).

    Google Scholar 

  • Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee on Internation Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–578.

    Article  PubMed  Google Scholar 

  • Kobe C, Dietlein M, Franklin J et al. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma – report on the second interim analysis of the PET investigation in the trial HD15 of the GHSG. Haematologica 2007;92(Suppl 5):CO21.

    Google Scholar 

  • Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62–68.

    Article  PubMed  CAS  Google Scholar 

  • Lavoie JC, Connors JM, and Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106(4):1473–1478.

    Article  PubMed  CAS  Google Scholar 

  • Macdonald DA, Ding K, Gospodarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 2007;18(10):1680–1684.

    Article  PubMed  CAS  Google Scholar 

  • Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.

    Article  PubMed  CAS  Google Scholar 

  • Noordijk E, Carde P, Hagenbeek A. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Six-year results of the EORTC-GPMC controlled clinical trials “H7-VF”, “H7-F” and “H7-U”. Presented at ASTRO; 1997.

    Google Scholar 

  • Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol (Meeting abstracts) 2005;23:6505.

    Google Scholar 

  • Noordijk, EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Oranization for Research and Treatment of Cancer (EORTC) H7 randomized controlled trials. J Clin Oncol 2006;24:3128–3135.

    Article  PubMed  Google Scholar 

  • Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 1988;80(18): 1466–1473.

    Article  PubMed  CAS  Google Scholar 

  • Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48(9):1721–1727.

    Article  PubMed  Google Scholar 

  • Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 2001;19:4238–4244.

    PubMed  CAS  Google Scholar 

  • Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. Ann Hematol 2007;86:897–903.

    Article  PubMed  Google Scholar 

  • Sieber M, Franklin J, Tesch H. Two Cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group (GHSG) Trial HD7. Leuk Lymphoma 2002;43(Suppl 2):52.

    Google Scholar 

  • Sieniawski, M, Franklin J, Nogova, L et al. Outcome of patientS experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s Lymphoma. J Clin Oncol 2007;25(15):2000–2005.

    Article  PubMed  Google Scholar 

  • Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 1998;16:830–843.

    PubMed  CAS  Google Scholar 

  • Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104: 3483–3489.

    Article  PubMed  CAS  Google Scholar 

  • Thomas J, Ferme C, Noordijk EM, et al. EORTC lymphoma group; groupe d’études des lymphomes adultes (GELA). Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Haematologica 2007;92(s5):27.

    Google Scholar 

Further Reading

  • Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004;22: 2835–2841.

    Article  PubMed  Google Scholar 

  • Carde P, Noordijk EM, Hagenbeek A, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial (Meeting abstract). J Clin Oncol 1997;16:16.

    Google Scholar 

  • Chisesi T, Federico M, Levis A, et al. ABVD versus stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Ann Oncol 2002;13(Suppl 1):102–106.

    Article  PubMed  Google Scholar 

  • Cosset J. MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin’s lymphoma: preliminary results of the EORTC-GELA H8-U randomized trial (no. 20931) in 995 patients. Leuk Lymphoma 2001;42:12.

    Google Scholar 

  • Girinsky T, van der Maazen, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lumphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.

    Article  PubMed  Google Scholar 

  • Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol 2004;15:276–282.

    Article  PubMed  CAS  Google Scholar 

  • The NCCN Hodgkin Disease/Lymphoma Guidelines (Version 2.2008) in The Complete Library of NCCN Clinical Practice Guidelines in Oncology™ [CD-ROM] (March 2009). Fort Washington, Pennsylvania: © 2008 National Comprehensive Cancer Network, Inc; 2009.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

    Hans T. Chung MD

  2. Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Stephen L. Shiao MD, PhD & Naomi R. Schechter MD

Authors
  1. Hans T. Chung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen L. Shiao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naomi R. Schechter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Div. Radiation Oncology, Oregon Clinic, SW. Barnes Rd. 9205, Portland, 97225, Oregon, USA

    Eric K. Hansen

  2. Department of Radiation Oncology, University of California, San Francisco, Divisadero Street, Suite H-1031 1600, San Francisco, 94143, California, USA

    Mack Roach

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag New York

About this chapter

Cite this chapter

Chung, H.T., Shiao, S.L., Schechter, N.R. (2010). Hodgkin’s Lymphoma. In: Hansen, E., Roach, M. (eds) Handbook of Evidence-Based Radiation Oncology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92988-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92988-0_35

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92987-3

  • Online ISBN: 978-0-387-92988-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation